Minerva Begins Global Phase 3 Trial for Roluperidone
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 31 2026
0mins
Minerva announced that the first patient has been screened in its global, confirmatory Phase 3 clinical trial evaluating roluperidone as monotherapy for the treatment of negative symptoms of schizophrenia.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NERV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NERV
Wall Street analysts forecast NERV stock price to fall
2 Analyst Rating
0 Buy
2 Hold
0 Sell
Hold
Current: 5.300
Low
4.00
Averages
4.50
High
5.00
Current: 5.300
Low
4.00
Averages
4.50
High
5.00
About NERV
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Minerva Neurosciences Q1 Earnings Report
- Earnings Miss: Minerva Neurosciences reported a Q1 non-GAAP EPS of -$0.17, missing expectations by $0.04, indicating ongoing challenges in achieving profitability amidst a competitive landscape.
- Cash Position: As of March 31, 2026, Minerva had approximately $78.2 million in cash, cash equivalents, marketable securities, and restricted cash, down from $82.4 million at December 31, 2025, highlighting pressures on the company's liquidity management.
- Market Reaction: The earnings miss may undermine investor confidence, potentially leading to increased stock price volatility, which could further impact the company's ability to raise funds and pursue growth initiatives.
- Strategic Reevaluation: Given the persistent financial losses and declining cash flow, Minerva may need to reassess its R&D investments and operational strategies to ensure sustainable growth in the highly competitive biopharmaceutical market.
See More
Minerva Neurosciences Gains on Market Outperform Rating for Roluperidone
- Market Outperform Rating: Citizens initiated coverage on Minerva Neurosciences (NERV) with a Market Outperform recommendation, citing a significant market opportunity for its lead candidate, roluperidone, in treating negative symptoms of schizophrenia.
- Clinical Trial Progress: Analyst Jason Butler highlighted that Minerva is advancing roluperidone in a Phase 3 confirmatory trial expected to yield data in H2 2027, and if results are positive, it could become the first U.S.-approved treatment for this condition.
- Market Potential Assessment: The initial target market for roluperidone is approximately 650,000 schizophrenia patients with pronounced negative symptoms but stable positive symptoms, with projected peak U.S. sales of $1.9 billion by 2034, based on a 65% probability of approval and 20% peak penetration.
- Strategic Significance: Butler argues that roluperidone has the potential to be the first approved therapy specifically targeting negative symptoms of schizophrenia, which would not only generate substantial revenue for Minerva but also potentially establish a new treatment standard in mental health.
See More
Minerva Neurosciences Files $200M Shelf Registration for Securities Offering
- Shelf Registration Filing: Minerva Neurosciences has filed a $200 million shelf registration, allowing the company to offer various securities, including common stock, preferred stock, debt securities, and warrants, thereby enhancing its financing flexibility to support future R&D and operations.
- Potential Use of Proceeds: The funds raised from this offering may be directed towards the development of Roluperidone, a treatment for negative symptoms of schizophrenia, further strengthening Minerva's competitive position in the mental health market.
- Financial Performance Overview: The latest financial report indicates a GAAP EPS of -$25.51 for Minerva Neurosciences, reflecting challenges in profitability that may impact investor confidence in its future financing plans.
- Market Reaction Expectations: The market response to Minerva's shelf registration is cautious, as while the financing plan could provide necessary capital support, the current financial condition may limit investor enthusiasm.
See More
Minerva Neurosciences Reports Q4 2025 Financial Results
- Financial Performance: Minerva Neurosciences reported a GAAP EPS of -$25.51 for Q4 2025, indicating significant challenges in profitability that may impact investor confidence.
- Cash Position: As of December 31, 2025, the company had approximately $82.4 million in cash, cash equivalents, and restricted cash, a substantial increase from $21.5 million at the end of 2024, reflecting significant progress in financing.
- Funding Context: The increase in cash and equivalents was primarily due to a private placement in October 2025, providing the necessary liquidity to support future R&D and operations.
- R&D Outlook: Minerva Neurosciences is discussing Roluperidone as a potential first treatment for negative symptoms of schizophrenia, which, if successful, could open new market opportunities and improve its financial situation.
See More
Minerva Neurosciences to Host KOL Event on Schizophrenia Treatment
- KOL Event Announcement: Minerva Neurosciences will host a virtual KOL event on February 3, 2026, featuring experts in psychology and psychiatry to discuss the patient burden of negative symptoms of schizophrenia and assessment challenges, which is expected to provide critical insights for the upcoming Phase 3 trial.
- Clinical Trial Plans: The company plans to initiate a confirmatory Phase 3 trial in 2026 using a novel protocol aligned with FDA considerations, aimed at maximizing the probability of a successful outcome and addressing the unmet medical need for treating negative symptoms.
- Impact of Negative Symptoms: Approximately 50% to 60% of individuals with schizophrenia experience at least one primary negative symptom, highlighting the urgent medical need as current antipsychotics primarily address positive symptoms without efficacy against negative symptoms.
- Expert Backgrounds: The event will feature Gregory Strauss, PhD, and Brian Kirkpatrick, MD, both of whom have extensive experience in schizophrenia research and have received over $82 million in research funding, underscoring their authority in the field and potential influence on future treatment options.
See More
Tuesday's Major Stock Market Highlights: Morning News Summary!
Stock Market News Overview: Tuesday features a wealth of stock market news that traders should monitor closely.
TipRanks Compilation: TipRanks has curated a list of the most significant stock market stories for today.
Importance for Traders: Staying updated on these stories is crucial for traders looking to make informed decisions.
Access to Full Stories: Readers can find all the top stock market stories by visiting TipRanks.
See More
Minerva Neurosciences Q1 Earnings Report
- Earnings Miss: Minerva Neurosciences reported a Q1 non-GAAP EPS of -$0.17, missing expectations by $0.04, indicating ongoing challenges in achieving profitability amidst a competitive landscape.
- Cash Position: As of March 31, 2026, Minerva had approximately $78.2 million in cash, cash equivalents, marketable securities, and restricted cash, down from $82.4 million at December 31, 2025, highlighting pressures on the company's liquidity management.
- Market Reaction: The earnings miss may undermine investor confidence, potentially leading to increased stock price volatility, which could further impact the company's ability to raise funds and pursue growth initiatives.
- Strategic Reevaluation: Given the persistent financial losses and declining cash flow, Minerva may need to reassess its R&D investments and operational strategies to ensure sustainable growth in the highly competitive biopharmaceutical market.
See More
Minerva Neurosciences Gains on Market Outperform Rating for Roluperidone
- Market Outperform Rating: Citizens initiated coverage on Minerva Neurosciences (NERV) with a Market Outperform recommendation, citing a significant market opportunity for its lead candidate, roluperidone, in treating negative symptoms of schizophrenia.
- Clinical Trial Progress: Analyst Jason Butler highlighted that Minerva is advancing roluperidone in a Phase 3 confirmatory trial expected to yield data in H2 2027, and if results are positive, it could become the first U.S.-approved treatment for this condition.
- Market Potential Assessment: The initial target market for roluperidone is approximately 650,000 schizophrenia patients with pronounced negative symptoms but stable positive symptoms, with projected peak U.S. sales of $1.9 billion by 2034, based on a 65% probability of approval and 20% peak penetration.
- Strategic Significance: Butler argues that roluperidone has the potential to be the first approved therapy specifically targeting negative symptoms of schizophrenia, which would not only generate substantial revenue for Minerva but also potentially establish a new treatment standard in mental health.
See More
Minerva Neurosciences Files $200M Shelf Registration for Securities Offering
- Shelf Registration Filing: Minerva Neurosciences has filed a $200 million shelf registration, allowing the company to offer various securities, including common stock, preferred stock, debt securities, and warrants, thereby enhancing its financing flexibility to support future R&D and operations.
- Potential Use of Proceeds: The funds raised from this offering may be directed towards the development of Roluperidone, a treatment for negative symptoms of schizophrenia, further strengthening Minerva's competitive position in the mental health market.
- Financial Performance Overview: The latest financial report indicates a GAAP EPS of -$25.51 for Minerva Neurosciences, reflecting challenges in profitability that may impact investor confidence in its future financing plans.
- Market Reaction Expectations: The market response to Minerva's shelf registration is cautious, as while the financing plan could provide necessary capital support, the current financial condition may limit investor enthusiasm.
See More
Minerva Neurosciences Reports Q4 2025 Financial Results
- Financial Performance: Minerva Neurosciences reported a GAAP EPS of -$25.51 for Q4 2025, indicating significant challenges in profitability that may impact investor confidence.
- Cash Position: As of December 31, 2025, the company had approximately $82.4 million in cash, cash equivalents, and restricted cash, a substantial increase from $21.5 million at the end of 2024, reflecting significant progress in financing.
- Funding Context: The increase in cash and equivalents was primarily due to a private placement in October 2025, providing the necessary liquidity to support future R&D and operations.
- R&D Outlook: Minerva Neurosciences is discussing Roluperidone as a potential first treatment for negative symptoms of schizophrenia, which, if successful, could open new market opportunities and improve its financial situation.
See More
Minerva Neurosciences to Host KOL Event on Schizophrenia Treatment
- KOL Event Announcement: Minerva Neurosciences will host a virtual KOL event on February 3, 2026, featuring experts in psychology and psychiatry to discuss the patient burden of negative symptoms of schizophrenia and assessment challenges, which is expected to provide critical insights for the upcoming Phase 3 trial.
- Clinical Trial Plans: The company plans to initiate a confirmatory Phase 3 trial in 2026 using a novel protocol aligned with FDA considerations, aimed at maximizing the probability of a successful outcome and addressing the unmet medical need for treating negative symptoms.
- Impact of Negative Symptoms: Approximately 50% to 60% of individuals with schizophrenia experience at least one primary negative symptom, highlighting the urgent medical need as current antipsychotics primarily address positive symptoms without efficacy against negative symptoms.
- Expert Backgrounds: The event will feature Gregory Strauss, PhD, and Brian Kirkpatrick, MD, both of whom have extensive experience in schizophrenia research and have received over $82 million in research funding, underscoring their authority in the field and potential influence on future treatment options.
See More
Tuesday's Major Stock Market Highlights: Morning News Summary!
Stock Market News Overview: Tuesday features a wealth of stock market news that traders should monitor closely.
TipRanks Compilation: TipRanks has curated a list of the most significant stock market stories for today.
Importance for Traders: Staying updated on these stories is crucial for traders looking to make informed decisions.
Access to Full Stories: Readers can find all the top stock market stories by visiting TipRanks.
See More
